The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
about
Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feelingLipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychoticsInflammation and the two-hit hypothesis of schizophrenia.Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis.Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophreniaImmune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies.Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia.Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia.Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.The nature of relapse in schizophrenia.Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models.Levels of S100B are raised in female patients with schizophrenia.IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia.Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia.Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study.Association of depression and psychotropic medication on cardiac-related outcomes in a nationwide community-dwelling elderly population in TaiwanBrain insulin dysregulation: implication for neurological and neuropsychiatric disorders.Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care.Is it time for immunopsychiatry in psychotic disorders?A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia.Depot risperidone-induced adverse metabolic alterations in female rats.Impaired monocyte activation in schizophrenia: ultrastructural abnormalities and increased IL-1β production.The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders.C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients.Physiological characteristics of patients with schizophrenia prematurely dying from circulatory diseases.Evaluating Diabetes Care for Patients With Serious Mental Illness Using the Chronic Care Model: A Pilot Study.Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia.Adverse Events in Childhood as a Risk Factor for Elevated BMI among People with Schizophrenia and Bipolar Disorder.Dopamine D2 Receptor Signaling in the Nucleus Accumbens Comprises a Metabolic-Cognitive Brain Interface Regulating Metabolic Components of Glucose Reinforcement.Expression levels of neuroimmune biomarkers in hypothalamus of allergic mice after phthalate exposure.Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis.
P2860
Q28244133-3D48BA4E-C7D7-4089-8AD6-783FA7829022Q28534822-46C77FBA-151A-469F-B69C-8BDC723B69E4Q30422062-51A6DA4B-A527-4D48-B2E7-5B04B98CDFDDQ30458875-46786565-0764-4F05-803E-0233D58588F1Q33598482-EC089F17-01D4-4AD2-B18F-30545AFE7EE7Q33601896-562E7189-BF9D-4B2C-8F6B-05EAF55F747DQ33688651-79B5DD87-6F29-4F33-A61D-AC0AE54BC85FQ33809544-BAFC7897-2105-4F57-B712-96434CB02E5EQ34248044-7F479581-3CDD-47E0-BD19-35FC2ACB22A2Q34581127-D1E96241-4507-4B11-BDEF-8466F88D4460Q34734936-BCE3622D-C6D4-4ADF-AC43-9DE2684625AEQ34738782-6D397A10-A062-443D-B97C-3338E7FBEDA5Q34764938-506211F2-E64E-4F97-A7F4-30488AC217DBQ37067281-B3EF090C-A6A6-41DB-8F56-BCF9B2C5BD13Q37079070-A96A2ED2-E9C5-46EF-85DF-4643B84444C2Q37165076-D3885589-9B34-415F-9BBD-C54E125083F5Q38075505-16089CE0-9C1A-4D39-90EA-0EAA5F379087Q38209914-5674E10D-BC57-4089-976D-FCC680E9A861Q38469831-21EF2598-2FD3-447C-8C71-AE14A2EE6CBDQ38779149-27E611A6-FEB7-4D86-9F29-BCC2D05CC389Q38801096-8869BE8F-CFC5-4463-A220-1A5DBC2A2211Q38873420-43514392-E7AD-4D48-98FD-4CA2F96931A0Q38896911-5B1D79BD-9733-4019-8C22-5E82256ECDBCQ38955820-CAF076CE-67E5-4FBD-8424-CE88D6F9B89EQ39311356-108D44F1-C782-4FD4-83FF-1A6520CDA978Q40599281-0571703B-660A-45EF-A909-1A3F368405ADQ42375568-15AF4E77-A68A-492D-B907-B7F8BD129FABQ47194564-B9F4823E-8115-4C40-B49E-8C654CBDD1C0Q47926819-A3EBA6D7-FB16-4C28-BE1E-B70FA638D8FEQ48060287-F290D61F-01CA-4FE8-903D-BBCA6B3F3A64Q48297514-A33E8BDB-1B7C-49BB-ADC2-F00FC88A43FCQ52755746-2C046B2F-BFB4-4465-94FD-D797D6AE76AA
P2860
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
@en
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
@nl
type
label
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
@en
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
@nl
prefLabel
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
@en
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
@nl
P2093
P2860
P921
P356
P1476
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
@en
P2093
Aye Mu Myint
Brian E Leonard
Markus Schwarz
P2860
P356
10.1177/0269881111431622
P407
P433
P577
2012-04-02T00:00:00Z